Swedish Orphan Biovitrum AB (FRA:B6E)
€ 24.42 -0.08 (-0.33%) Market Cap: 8.36 Bil Enterprise Value: 10.02 Bil PE Ratio: 42.61 PB Ratio: 2.56 GF Score: 88/100

Swedish Orphan Biovitrum AB (publ) to Acquire CTI Biopharma Corp Call Transcript

May 10, 2023 / 01:00PM GMT
Release Date Price: €22.11 (-0.60%)
Operator

Ladies and gentlemen, welcome to the acquisition on CTI BioPharma Conference Call in live webcast. I'm Andre, the Chorus Call operator. (Operator Instructions) The presentation will be followed by a Q&A session.(Operator Instructions) At this time, it's my pleasure to hand over to Guido Oelkers. Please go ahead, sir.

Guido Oelkers;publ;CEO;President
Swedish Orphan Biovitrum AB

()-&

Yes. Thank you so much, and welcome, everybody. Thanks for your interest in Sobi and our latest activity in an effort to acquire CTI BioPharma Corporation. And we will want to talk a little bit more about this deal and lead you into our rationale. Before I do this, please take note of the forward-looking statement as per usual. And on the next page, you find important information with regard to this potential transaction. So I just want to draw your attention to the fact that we have signed a definitive agreement, but obviously, the deal has not been closed. With this said, please move to the next page, who is going to share

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot